TWM582392U - Astaxanthin complex preparation system - Google Patents

Abstract

The invention provides an astaxanthin complex preparation system. The system includes a mixing unit and an additive-adding unit, which operate sequentially to prepare a compound astaxanthin complex. Astaxanthin inclusion complex is provided for the preparation system. The mixing unit adds other active ingredients into the astaxanthin inclusion complex to prepare a compound mixture; and the additive-adding unit adds safe and reliable food additives to the compound mixture for adsorbing oily material and moisture content, and thus to prepare a stable and sustainably active compound astaxanthin complex with long shelf-life, which can bring favorable effects on regulating the lipid profile.

Description

Astaxanthin compound composition preparation system

The present invention discloses a preparation system of a lycopene compound composition, and more particularly to a preparation system of a lycopene compound composition containing a compound composition for improving the health care activity of the lycopene compound composition.

Astaxanthin, also known as astaxanthin, is a natural antioxidant that belongs to the class of carotenoids. Astaxanthin has excellent antioxidant capacity, especially the ability to scavenge free radicals, far superior to antioxidants such as beta-carotene, lutein and vitamin E. Recent studies have found that the antioxidant capacity of astaxanthin has a health-care effect on cardiovascular health, reduces the accumulation of oxidized low-density lipoprotein in the blood, and has superior health benefits. It has considerable potential for application in food, cosmetics, health food, medicine and other industries. .

However, because astaxanthin is insoluble in water and structurally unstable, it is easily affected by environmental factors such as light, heat, temperature, oxygen, acid and alkali, metal ions, water and gas, etc., and degrades activity and efficacy, and is usually not resistant to storage, often Limiting its application, there is still a need for improvement in preparation systems and methods.

Generally, the source of astaxanthin contains crustacean aquatic animals (shrimp, crab or its waste), green microalgae and special yeast, but the concentration is very low, which is difficult to supply sufficient health care products. In addition, if the astaxanthin is extracted from aquatic animals, in addition to the doubts about the specific ethnic allergies, the extraction quality and mass production efficiency of astaxanthin have become a major limitation in application. Therefore, improving the quality of astaxanthin products to fully utilize their health benefits is an important goal in the technical field.

One of the aims of the present invention is to provide a preparation system of a compound composition of astaxanthin for preparing a compound composition of astaxanthin which is stable in nature and has a blood lipid regulating effect.

According to the above object, the present invention discloses a preparation system of a lycopene compound composition, comprising: a mixing unit and an adding unit, wherein the mixing unit adds the sputum extract, the jujube extract and the amino acid to the astaxanthin-containing astaxanthin The clathrate is mixed and uniformly mixed to form a compound mixture; the addition unit adds at least one anti-caking agent to the compound mixture to form a compound composition of astaxanthin.

According to the above object, the present invention further discloses a preparation system of astaxanthin compound composition, wherein the astaxanthin inclusion compound contains diatomaceous powder, which comprises astaxanthin, and the concentration percentage of the astaxanthin contained therein is in the range of 1% to 20%, may also be 5% to 10% or 10% to 20%, and a preferred weight percentage concentration is between 1% and 5%.

According to the above object, the present invention further discloses a preparation system of a lycopene compound composition, wherein the weight percentage of the ruthenium-containing extract of the lycopene compound composition ranges from 0.1% to 5% and the weight percentage of the jujube-containing extract Concentrations range from 0.1% to 5%.

According to the above object, the present invention further discloses a preparation system of a lycopene compound composition, wherein the amino acid is arginine, and the concentration of arginine in the composition of the lycopene compound is in the range of 10% to 90% by weight. %.

According to the above object, the present invention further discloses a preparation system of astaxanthin compound composition, wherein the anti-caking agent is selected from the group consisting of calcium citrate, cerium oxide, potassium ferrocyanide, tricalcium phosphate, magnesium oxide, and microcrystalline fiber. a group of primes, cyclodextrins, and combinations thereof.

In order to make the purpose, technical features and advantages of the present invention more familiar to those skilled in the relevant art, and to implement the present invention, the technical features and implementations of the present invention are specifically illustrated with the accompanying drawings. The preferred embodiment is further illustrated. The schemas referenced below are intended to convey an indication of the features of the present invention and are not required to be completely drawn according to the actual situation. The technical content that is well known to those skilled in the art in the embodiments is not described.

First, referring to Fig. 1, a block diagram of the preparation system of the astaxanthin compound composition of the present invention. The present astaxanthin compound composition preparation system 10 comprises two units: a mixing unit 14 and an adding unit 16, both of which are used sequentially to prepare a component of the astaxanthin. According to a preferred embodiment of the present invention, an astaxanthin inclusion compound is first provided, which has good stability and can stably maintain the activity of astaxanthin for use in the operation of the astaxanthin compound composition preparation system 10. In the astaxanthin compound composition preparation system 10, the main function of the mixing unit 14 is to add the other compound active ingredients to the astaxanthin clathrate and uniformly mix to prepare a compound mixture, wherein the preferred compound active ingredients include hydrazine. The main function of the extract, the jujube extract and the amino acid; and the adding unit 16 is to use a safe and reliable food additive to be added to the compound mixture, thereby adsorbing the oily substance and the water, and finally forming a stable property and a long active period. Resin-resistant astaxanthin combination composition.

Please also refer to Figure 2 for a flow chart of the steps of implementing this creation. Step S1 is to provide a astaxanthin inclusion compound for use in a subsequent step, wherein the raw material source and type of the inclusion complex are not limited, as long as the inclusion compound contains high stability, sufficient amount and long-term maintenance of active astaxanthin That applies to this creation. Step S2 is to perform a mixing step to form a compound mixture. Specifically, the cerium extract, the jujube extract and the amino acid are added to the aforementioned clathrate and uniformly mixed to form a compound mixture. Subsequent step S3 is followed by performing an addition step to form the astaxanthin combination composition. It is specifically carried out by adding an anti-caking agent to the aforementioned compound mixture to form a compound composition of astaxanthin. Details of the implementation of the steps and related instructions are detailed below.

Regarding the source of astaxanthin, the main source of astaxanthin on the market is crustacean aquatic animals (including its waste) such as shrimp and crab, and microalgae, yeast (Phaffiarhodozyma), etc. Allergic concerns and vegetarian consumer demand, the implementation of this creation is preferably the use of Haematococcus source materials, wherein the species of Haematococcus includes, but not limited to, Haematococcus pluvialis . This refers to the "raw material of Haematococcus" refers to the raw material made of Haematococcus, which can be its broken-wall freeze-dried powder, crude extract or commercially available Haematococcus raw material, which contains shrimp red in the raw material. If the concentration of the pigment is greater than 1%, it is suitable for this creation. For the sake of explanation, the following description refers to the raw material of Haematococcus as "Hypococcus algae powder".

More specifically, according to a preferred embodiment of the present invention, the source of the Haematococcus powder is Haematococcus pluvialis, and in one embodiment, the weight percentage of the rhodococcus powder to the rhodococcus powder is 1% to 20%. In another embodiment, the weight percentage of the rhodococcus powder to the rhodococcus powder is 10% to 20%; in still another embodiment, the weight percentage of the rhodococcus powder to the rhodococcus powder From 5% to 10%; and preferred embodiments, the weight percentage of the rhodococcus powder to the rhodococcus powder is from 1% to 5%.

The combination of the active ingredients and the raw materials of the Chinese side can often improve the health benefits. The present application further uses the extracts derived from the sorghum and jujube as the active components of the compound, and is used together with the amino acid to enhance the compound composition of the astaxanthin prepared by the present preparation. The regulation of blood lipids. As is well known, sputum contains carotene, betaine, vitamin A, vitamin B1, vitamin B2, vitamin C, calcium, phosphorus, iron, etc., and many studies have confirmed that 枸杞 is beneficial to cardiovascular health. Jujube is rich in vitamin C and protein, fat, sugar, vitamin B, calcium, iron, triterpenes (Cyclic AMP), pharmacological studies have confirmed that red dates protect the liver, improve blood Oxygen, expansion of blood vessels and other effects.

According to the concept of the compound, the mixing unit 14 of the astaxanthin compound composition preparation system 10 of the present invention further adds the sputum extract, the jujube extract and the amino acid to the aforementioned astaxanthin inclusion compound and uniformly mixes, thereby forming Compound mixture. Regarding the selection of the extract of medlar and the extract of jujube, the creation is not particularly limited, and it can be extracted from the raw materials of medlar and jujube plants by itself, and the commercially available sputum extract and the raw material of jujube extract can also be used.

Among them, regarding the selection of the amino acid in the mixing unit 14, the creation is not particularly limited, as long as it is beneficial to the human body for use in the present invention, including but not limited to a variety of essential amino acids such as tryptophan, knots. (valine), threonine, lysine, phenylalanine, leucine, isoleucine, methionine, histamine Acid (histidine), arginine (Arginine), etc.; but depending on the modern life style and easy to consume a lot of nutritious needs, preferably arginine.

Finally, in order to improve the overall singularity, activity and storage time of the health care product, the additive unit 16 of the astaxanthin compound composition preparation system 10 of the present invention further adds an anti-caking agent to the compound mixture to form a shrimp red. Compound composition. There is no restriction on the choice of anti-caking agents, as long as they are legally added anti-caking agents, such as: calcium citrate, cerium oxide, potassium ferrocyanide, tricalcium phosphate, oxidation Magnesium, microcrystalline cellulose, cyclodextrin, etc., and those skilled in the art can also use the above anti-caking agent in any combination according to the purpose of use and the anti-caking effect. According to a preferred embodiment of the present invention, the anti-caking agent may be selected by separately adding calcium citrate or cerium oxide, or adding calcium citrate and cerium oxide, wherein the effect of adding calcium citrate and cerium oxide is more. Ideally, in addition to preventing agglomeration of the composition of the astaxanthin compound, the effect of oil absorption, water absorption and fluidity can be achieved, which facilitates the subsequent processing of the astaxanthin compound composition.

After obtaining the compound composition of the astaxanthin, the astaxanthin compound composition can be further prepared into different dosage forms such as hard capsules, soft capsules, powder packets, tablets, drinks, etc. according to the product form, using a suitable filling, pressing or processing process. product. The details of the related filling, pressing or processing processes are well known to those skilled in the relevant art and will not be described again.

The astaxanthin compound composition prepared according to the preparation of the astaxanthin compound composition preparation system 10 has an excellent blood lipid regulating effect, as explained in the following experimental examples.

Experimental Example 1: Animal test for lowering blood fat

The blood-lowering test animals were treated with Syrian male hamsters, aged 6-7 weeks, divided into 6 groups, 8 rats in each group, a total of 48, the test was for 8 weeks, and the test method was used to feed the shrimp red. Compound composition. Dosage calculation is based on adult dosage (up to 250 mg of astaxanthin compound per day for 60 kg body weight, as 1 dose), 1 time (hamster dose 30.83 mg/kg), 2 times (hamster dose 61.67) Mg/kg) and 3 times (hamster dose 92.50 mg/kg) dose test, and clinical hypolipidemic drugs (Probucol) as a comparison of hypolipidemic activity, the overall experimental design and grouping are shown in Table 1.  Table 1: Antihyperlipidemic effect animal test design and group test group (code) feed type  Substance  Animal dose  (mg/kg body weight)  General control (NOR) normal feed  RO water  -  Blank control (HC) high cholesterol feed  RO water  -  Active control (P) high cholesterol feed  Probucol  124  1 time dose (AL) high cholesterol feed  Astaxanthin compound composition powder  30.83  2 times dose (AM) high cholesterol feed  Astaxanthin compound composition powder  61.67  3 times dose (AH) high cholesterol feed  Astaxanthin compound composition powder  92.50  

Biostatistical analysis method: The results of the test were statistically processed by one-way ANOVA of SPSS 10.1 system, and the difference between groups was compared by Duncan's Multiple Range Test. p < 0.05 indicates significant difference. .

Test result 1: Changes in total cholesterol and triglyceride concentrations in the blood

The experimental animals were sacrificed to draw blood, and their serum total cholesterol (TC) and triglyceride (TG) results were shown in Table 2. The total cholesterol and triglyceride in the control group were significant. Below the blank control group (p < 0.05), it was indicated that the high cholesterol diet pattern of the blank control group did successfully induce hyperlipidemia characterization in the test animals. Regarding the results of the test group, it was found from the total cholesterol results that the 2-fold dose group and the 3-fold dose group and the active control were significantly lower than the blank control group (p < 0.05), and the triglyceride results showed that The 2-fold dose group was significantly lower than the blank control group (p < 0.05). From the above results, it can be known that the double dose of the astaxanthin compound composition prepared by the present invention can significantly reduce the serum total cholesterol concentration increased by the high cholesterol diet, and the triglyceride can be significantly reduced when the dose is 3 times. Ester concentration.  Table 2: Total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and LDL- in serum of hamsters fed with different test substances. Effect of C/HDL-C ratio Test group (code) TC (mg/dL) TG (mg/dL) HDL-C (mg/dL) LDL-C (mg/dL) LDL-C / HDL-C ratio LDL-C / TCHDL-C / TC General Control (NOR) 85±9  79±10  49±4  10.8±3.3  0.217±0.055  0.124 ± 0.027  0.771 ± 0.045  Blank control (HC) 177±9  155±30  89±4  43.9±3.2  0.494±0.044  0.247 ± 0.011  0.670 ± 0.038  Active control (P) 157±11  152±14  83±11  31.8±3.9  0.392±0.110  0.203 ± 0.032  0.707 ± 0.066  1 times dose (AL) 162±17  134±24  85±7  37.9±3.8  0.444±0.041  0.234 ± 0.018  0.705 ± 0.037  2 times dose (AM) 141±15  136±21  78±10  36.8 ± 3.6  0.482±0.091  0.263 ± 0.040  0.799 ± 0.055  3 times dose (AH) 141±24  112±21  79±12  38.5±5.5  0.490±0.047  0.275 ± 0.023  0.803 ± 0.039  

Test result 2: Changes in HDL-C and LDL-C in blood

For the effect of astaxanthin combination on high cholesterol diet hamster serum high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), please continue to see Table 2. The HD control group increased the HDL-C and LDL-C by feeding a high-cholesterol diet, and was significantly different from the general control group (p < 0.05); while the 1-fold dose group, the 2-fold dose group and the 3-fold dose group The concentration of LDL-C was significantly lower than that of the blank control group (p < 0.05).  Table 3: Effect of feeding different test substances on total cholesterol (TC) and triglyceride (TG) content in liver and feces of hamsters Test group (code) Liver feces TC  (mg/g)  TG  (mg/g)  TC  (mg/g)  TG  (mg/g)  General Control (NOR) 3.40 ± 0.31  16.3 ± 1.9  7.8 ± 1.6  17.0 ± 2.4  Blank control (HC) 4.92 ± 0.77  16.7 ± 2.7  13.8 ± 4.2  17.5 ± 8.3  Activity Control (P) 3.80 ± 0.26  13.7 ± 1.5  6.7 ± 0.9  15.8 ± 2.8  1 time dose (AL) 3.76 ± 0.41  15.5 ± 3.1  7.3 ± 1.3  15.9 ± 2.9  2 times dose (AM) 3.62 ± 0.26  16.2 ± 2.2  9.4 ± 1.2  14.7 ± 2.5  3 times dose (AH) 3.56 ± 0.37  14.6 ± 1.9  8.1 ± 0.9  14.5 ± 2.8  

Test result 3: Changes in total cholesterol and triglyceride concentrations in liver and feces

When the concentration of total cholesterol and triglyceride in the liver is too high, the risk of developing fatty liver may increase. The changes in total cholesterol and triglyceride concentration in the liver and feces of the experimental animals in this experimental example are shown in Table 3. In the control group, the total cholesterol was significantly higher than that in the general control group (p < 0.05) due to the high cholesterol diet, and in the liver of the test animals in the 1-fold dose group, the 2-fold dose group, the 3-fold dose group, and the active control group. The total cholesterol concentration was significantly lower than that of the blank control group (p < 0.05), and the dose effect was observed, indicating that the astaxanthin combination composition may have the effect of preventing fatty liver.

Decreased cholesterol and triglyceride levels may be inhibited by the path of production or absorption, or may be excreted through the feces, so the combination of total cholesterol and triglyceride in the feces can be used to eat the combination of astaxanthin. Whether the substance can promote the excretion of cholesterol and triglyceride. According to the test results, the total cholesterol content in the feces of the 1x dose group, the 2x dose group and the 3x dose group was significantly lower than that of the blank control group (p < 0.05); but for the triglyceride in the feces The glyceride content had no significant effect (p < 0.05), indicating that a dry powder of the edible lycopene combination composition may help reduce cholesterol synthesis and thereby reduce fecal triglyceride levels.

The above description is only the preferred embodiment of the present invention, and is not intended to limit the scope of the present invention; the above description should be understood and implemented by those skilled in the relevant art, so that the other disclosures are not disclosed. Equivalent changes or modifications made under the spirit shall be included in the scope of the patent application.

10‧‧‧Sheyin compound composition preparation system

14‧‧‧Mixed unit

16‧‧‧Adding unit

S1‧‧‧Step S1

S2‧‧‧Step S2

S3‧‧‧Step S3

Figure 1 is a block diagram of the preparation system of the astaxanthin compound composition of the present invention.  Figure 2 is a flow chart showing the steps of implementing the creation.  

Claims (8)

A shrimp compound composition preparation system comprising:  a mixing unit which adds a sputum extract, a jujube extract and an amino acid to a clathrate and uniformly mixes to form a compound mixture;  An addition unit that adds at least one anti-caking agent to the compound mixture to form a compound composition of astaxanthin.   The astaxanthin compound composition preparation system according to claim 1, wherein the inclusion compound contains diatomaceous powder, and the weight percentage of the lycopene compound composition accounts for 10%-30%. The astaxanthin compound composition preparation system according to claim 1 or 2, wherein the red algae powder contains astaxanthin, and the aspergillus accounts for the weight percentage of the rhodococcus powder. Between 1% and 20%. The astaxanthin compound composition preparation system according to claim 1, wherein the sputum extract comprises the aspergillus compound composition in a concentration percentage of 0.1% to 5% by weight. The astaxanthin compound composition preparation system according to claim 1, wherein the jujube extract comprises the aspergillus compound composition in a concentration percentage of 0.1% to 5% by weight. The astaxanthin compound composition preparation system according to claim 1, wherein the amino acid is arginine. The astaxanthin compound composition preparation system according to claim 6 , wherein the arginine comprises the aspergillus compound composition in a concentration percentage of 10% to 90% by weight. The astaxanthin compound composition preparation system according to claim 1, wherein the anti-caking agent is calcium citrate, cerium oxide, potassium ferrocyanide, tricalcium phosphate, magnesium oxide, microcrystalline fiber. a group of primes, cyclodextrins, and combinations thereof.